September 14, 2022
Article
“Responses occurred across all International mRCC Database Consortium risk groups—both in the favorable and intermediate/poor risk groups,” said Jamie R. Merchan, MD.
May 17, 2022
Article
“[Mitomycin gel] is efficacious as a [chemoablation] agent in adult patients with low-grade upper tract urothelial cancer, and while it’s FDA approved for both antegrade and retrograde administration, prior reports are limited to the retrograde experience,” said study investigator Kyle Rose, MD.
September 13, 2021
Article
The 12-month recurrence-free survival rate was 42.9% for those who received BCG alone compared with 44.4% for those who received the combination.
September 11, 2021
Article
Long-term findings from 2 cohorts of a phase 3 study showed sustained efficacy with the novel intravesical gene therapy in patients with BCG-unresponsive non–muscle invasive bladder cancer.